Targeting the glucocorticoid receptor in breast and prostate cancers

Science Translational Medicine

Volumn 7, Issue 305, 2015, Pages

  Kach, Jacob ^a   Conzen, Suzanne D ^a,b   Szmulewitz, Russell Z ^a  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ANTIESTROGEN; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ANTAGONIST; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PROGESTERONE RECEPTOR; RADIUM CHLORIDE RA 223; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SIPULEUCEL T; AR PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN;

AMINO TERMINAL SEQUENCE; ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; APOPTOSIS; BONE METASTASIS; BREAST CANCER; CANCER INHIBITION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CASTRATION RESISTANT PROSTATE CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CONFORMATIONAL TRANSITION; DIMERIZATION; DRUG ANTAGONISM; DRUG EFFICACY; HUMAN; LIGAND BINDING; METASTASIS POTENTIAL; PLEIOTROPY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN TARGETING; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR ESCAPE; TUMOR GROWTH; ANIMAL; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; MALE; METABOLISM; PROSTATIC NEOPLASMS; TRANSLATIONAL RESEARCH;

ANIMALS; BREAST NEOPLASMS; CELL SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84941755779     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aac7531     Document Type: Review

References (34)

1. R. Z. Szmulewitz, in Cancer Biology Review: A Case-Based Approach, W. M. Sadler, Ed. (Demos Medical Publishing, New York, 2014), pp. 85-86.
2. P. E. Lonergan, D. J. Tindall, Androgen receptor signaling in prostate cancer development and progression. J. Carcinog. 10, 20 (2011).
3. K. S. Korach, J. F. Couse, S. W. Curtis, T. F. Washburn, J. Lindzey, K. S. Kimbro, E. M. Eddy, S. Migliaccio, S. M. Snedeker, D. B. Lubahn, D. W. Schomberg, E. P. Smith, Estrogen receptor gene disruption: Molecular characterization and experimental and clinical phenotypes. Recent Prog. Horm. Res. 51, 159-186, discussion 186-188 (1996).
4. N. A. Samaan, A. U. Buzdar, K. A. Aldinger, P. N. Schultz, K. P. Yang, M. M. Romsdahl, R. Martin, Estrogen receptor: A prognostic factor in breast cancer. Cancer 47, 554-560 (1981).
5. H. I. Scher, C. L. Sawyers, Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23, 8253-8261 (2005).
6. C. M. Perou, T. Sø'rlie, M. B. Eisen, M. Van De Rijn, S. S. Jeffrey, C. A. Rees, J. R. Pollack, D. T. Ross, H. Johnsen, L. A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S. X. Zhu, P. E. Lø'nning, A. L. Bø'rresen-Dale, P. O. Brown, D. Botstein, Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
7. C. I. Herold, C. K. Anders, New targets for triple-negative breast cancer. Oncology 27, 846-854 (2013).
8. M. Fakih, C. S. Johnson, D. L. Trump, Glucocorticoids and treatment of prostate cancer: A preclinical and clinical review. Urology 60, 553-561 (2002).
9. I. F. Tannock, D. Osoba, M. R. Stockler, D. S. Ernst, A. J. Neville, M. J. Moore, G. R. Armitage, J. J. Wilson, P. M. Venner, C. M. Coppin, K. C. Murphy, Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J. Clin. Oncol. 14, 1756-1764 (1996).
10. Ludwig Breast Cancer Study Group, A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res. 45, 4454-4459 (1985).
11. O. Gluz, C. Liedtke, N. Gottschalk, L. Pusztai, U. Nitz, N. Harbeck, Triple-negative breast cancer-current status and future directions. Ann. Oncol. 20, 1913-1927 (2009).
12. B. D. Keith, Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy. BMC Cancer 8, 84 (2008).
13. S. Karmakar, Y. Jin, A. K. Nagaich, Interaction of glucocorticoid receptor (GR) with estrogen receptor (ER) α and activator protein 1 (AP1) in dexamethasone-mediated interference of ERα activity. J. Biol. Chem. 288, 24020-24034 (2013).
14. K. Nishimura, N. Nonomura, Y. Yasunaga, N. Takaha, H. Inoue, H. Sugao, S. Yamaguchi, O. Ukimura, T. Miki, A. Okuyama, Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89, 2570-2576 (2000).
15. C. J. Ryan, M. R. Smith, J. S. De Bono, A. Molina, C. J. Logothetis, P. De Souza, K. Fizazi, P. Mainwaring, J. M. Piulats, S. Ng, J. Carles, P. F. Mulders, E. Basch, E. J. Small, F. Saad, D. Schrijvers, H. Van Poppel, S. D. Mukherjee, H. Suttmann, W. R. Gerritsen, T. W. Flaig, D. J. George, E. Y. Yu, E. Efstathiou, A. Pantuck, E. Winquist, C. S. Higano, M. E. Taplin, Y. Park, T. Kheoh, T. Grifin, H. I. Scher, D. E. RathkopfCOU-AA-302 Investigators, Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138-148 (2013).
16. A. Yemelyanov, J. Czwornog, D. Chebotaev, A. Karseladze, E. Kulevitch, X. Yang, I. Budunova, Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene 26, 1885-1896 (2007).
17. B. Sahu, M. Laakso, P. Pihlajamaa, K. Ovaska, I. Sinielnikov, S. Hautaniemi, O. A. Jänne, FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res. 73, 1570-1580 (2013).
18. V. K. Arora, E. Schenkein, R. Murali, S. K. Subudhi, J. Wongvipat, M. D. Balbas, N. Shah, L. Cai, E. Efstathiou, C. Logothetis, D. Zheng, C. L. Sawyers, Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155, 1309-1322 (2013).
19. M. Isikbay, K. Otto, S. Kregel, J. Kach, Y. Cai, D. J. Vander Griend, S. D. Conzen, R. Z. Szmulewitz, Glucocorticoid receptor activity contributes to resistance to androgentargeted therapy in prostate cancer. Horm. Cancer 5, 72-89 (2014).
20. D. Pan, M. Kocherginsky, S. D. Conzen, Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res. 71, 6360-6370 (2011).
21. M. J. Bolt, F. Stossi, J. Y. Newberg, A. Orjalo, H. E. Johansson, M. A. Mancini, Coactivators enable glucocorticoid receptor recruitment to fine-tune estrogen receptor transcriptional responses. Nucleic Acids Res. 41, 4036-4048 (2013).
22. D. Pang, M. Kocherginsky, T. Krausz, S. Y. Kim, S. D. Conzen, Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol. Ther. 5, 933-940 (2006).
23. M. N. Skor, E. L. Wonder, M. Kocherginsky, A. Goyal, B. A. Hall, Y. Cai, S. D. Conzen, Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin. Cancer Res. 19, 6163-6172 (2013).
24. T. B. Miranda, T. C. Voss, M. H. Sung, S. Baek, S. John, M. Hawkins, L. Grø'ntved, R. L. Schiltz, G. L. Hager, Reprogramming the chromatin landscape: Interplay of the estrogen and glucocorticoid receptors at the genomic level. Cancer Res. 73, 5130-5139 (2013).
25. A. Courtin, L. Communal, M. Vilasco, D. Cimino, N. Mourra, M. De Bortoli, D. Taverna, A. M. Faussat, M. Chaouat, P. Forgez, A. Gompel, Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res. Treat. 131, 49-63 (2012).
26. P. L. Shaffer, A. Jivan, D. E. Dollins, F. Claessens, D. T. Gewirth, Structural basis of androgen receptor binding to selective androgen response elements. Proc. Natl. Acad. Sci. U. S. A. 101, 4758-4763 (2004).
27. R. Z. Szmulewitz, E. Chung, H. Al-Ahmadie, S. Daniel, M. Kocherginsky, A. Razmaria, G. P. Zagaja, C. B. Brendler, W. M. Stadler, S. D. Conzen, Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate 72, 157-164 (2012).
28. N. Xie, H. Cheng, D. Lin, L. Liu, O. Yang, L. Jia, L. Fazli, M. E. Gleave, Y. Wang, P. Rennie, X. Dong, The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. Int. J. Cancer 136, E27-E38 (2015).
29. J. L. Mohler, Y. Chen, K. Hamil, S. H. Hall, J. A. Cidlowski, E. M. Wilson, F. S. French, M. Sar, Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Clin. Cancer Res. 2, 889-895 (1996).
30. E. E. Reyes, D. J. Vander Weele, M. Isikbay, R. Duggan, A. Campanile, W. M. Stadler, D. J. Vander Griend, R. Z. Szmulewitz, Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J. Transl. Med. 12, 313 (2014).
31. S. Carreira, A. Romanel, J. Goodall, E. Grist, R. Ferraldeschi, S. Miranda, D. Prandi, D. Lorente, J. S. Frenel, C. Pezaro, A. Omlin, D. N. Rodrigues, P. Flohr, N. Tunariu, J. S. De Bono, F. Demichelis, G. Attard, Tumor clone dynamics in lethal prostate cancer. Sci. Transl. Med. 6, 254ra125 (2014).
32. M. Anbalagan, B. Huderson, L. Murphy, B. G. Rowan, Posttranslational modifications of nuclear receptors and human disease. Nucl. Recept. Signal. 10, e001 (2012).
33. V. Stanišic, D. M. Lonard, B. W. O'Malley, Modulation of steroid hormone receptor activity. Prog. Brain Res. 181, 153-176 (2010).
34. X. Li, J. Wong, S. Y. Tsai, M. J. Tsai, B. W. O'Malley, Progesterone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Mol. Cell. Biol. 23, 3763-3773 (2003).